ESR1 and breast cancer: We demonstrated the additional benefit of dual HER2/HER3 blockage compared with single-agent lumretuzumab or pertuzumab alone in ER+ mouse xenograft models of human breast cancer that expressed HER3 and low levels of HER2 (Fig 2 and Table 1).